Flag of the European Union EU Clinical Trials Register Help

Clinical trials for >

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44399   clinical trials with a EudraCT protocol, of which   7411   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    438 result(s) found for: >. Displaying page 5 of 22.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2008-006425-14 Sponsor Protocol Number: PDX-014 Start Date*: 2009-07-02
    Sponsor Name:Allos Therapeutics, Inc
    Full Title: Phase 1/2 Study of Pralatrexate in Female Patients with Previously-treated Advanced or Metastatic Breast Cancer
    Medical condition: Previously-treated Advanced or Metastatic Breast Cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10027475 Metastatic breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: FR (Ongoing) HU (Completed) CZ (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-002293-41 Sponsor Protocol Number: AB12005 Start Date*: 2015-07-02
    Sponsor Name:AB Science
    Full Title: A prospective, multicenter, double-randomised, double-blind, 2-parallel groups, phase 3 study to compare as first line therapy efficacy and safety of masitinib in combination with gemcitabine, to g...
    Medical condition: Non resectable locally advanced or metastatic pancreatic cancer
    Disease: Version SOC Term Classification Code Term Level
    18.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033610 Pancreatic carcinoma metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) BE (Completed) DE (Prohibited by CA) SK (Prohibited by CA) GR (Completed) GB (Temporarily Halted)
    Trial results: (No results available)
    EudraCT Number: 2014-003836-38 Sponsor Protocol Number: MK-5172-077 Start Date*: 2015-02-16
    Sponsor Name:Merck Corporation, Inc.
    Full Title: A Phase III, Open-Label Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-5172/MK-8742 versus Sofosbuvir/Pegylated Interferon/Ribavirin (PR) in Treatment-Naïve and PR...
    Medical condition: Hepatitis C
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004848 10019751 Hepatitis C virus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) LT (Completed) ES (Completed) NO (Completed) HU (Completed) DK (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2018-000819-25 Sponsor Protocol Number: DS102A-05-AH1 Start Date*: 2019-01-31
    Sponsor Name:Afimmune
    Full Title: A Randomised, Double-Blind, Placebo-Controlled, Phase II Study to Assess the Efficacy and Safety of Orally Administered DS102 in Patients with Severe Acute Decompensated Alcoholic Hepatitis.
    Medical condition: Severe Acute Decompensated Alcoholic Hepatitis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004871 10001624 Alcoholic hepatitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Prematurely Ended) FR (Prematurely Ended) DE (Prematurely Ended) LV (Prematurely Ended) GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-002349-80 Sponsor Protocol Number: M13-583 Start Date*: 2015-11-13
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: A Single-Arm, Open-Label Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Adults with Chronic Hepatitis C Virus Genotype 4, 5, or 6 Infection (ENDURANCE-4)
    Medical condition: Chronic Hepatitis C Virus Genotype 4, 5 or 6 Infection
    Disease: Version SOC Term Classification Code Term Level
    18.1 10021881 - Infections and infestations 10008912 Chronic hepatitis C PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PT (Completed) BE (Completed) GB (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2011-002203-15 Sponsor Protocol Number: PregMet2 Start Date*: 2012-08-08
    Sponsor Name:NTNU, Norwegian University of Science and Technology
    Full Title: Metformin treatment of pregnant PCOS women and prevention of late miscarriages and preterm birth The PregMet 2 Study
    Medical condition: Poly Cystic Ovarial Syndrome (PCOS) in pregnant women. PCOS should be diagnosed according to the Rotterdam Consensus criterias: - at least 2 out of 3 criterias 1.PCO in at least one ovary 2.Olig...
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004872 10065161 Polycystic ovarian syndrome LLT
    Population Age: Adults Gender: Female
    Trial protocol: NO (Completed) SE (Completed) IS (Completed)
    Trial results: View results
    EudraCT Number: 2009-015703-13 Sponsor Protocol Number: InReTel Start Date*: 2009-12-11
    Sponsor Name:Klinik für Innere Medizin II der Klinikum Chemnitz gGmbH
    Full Title: The influence of Telmisartan on insulin resistance and fatty liver in patients suffer from hypertension
    Medical condition: Influence of Telmisartan on insulin resistance, hypertension, non-alcoholic fatty liver
    Disease: Version SOC Term Classification Code Term Level
    12.0 10020772 Hypertension LLT
    12.0 10052066 Metabolic syndrome LLT
    12.0 10022489 Insulin resistance LLT
    12.0 10016261 Fatty liver LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2013-004688-30 Sponsor Protocol Number: 15892A Start Date*: 2014-05-19
    Sponsor Name:H. Lundbeck A/S
    Full Title: Interventional, open-label study of 18 mg Selincro® as needed use, in the treatment of patients with alcohol dependence in primary care
    Medical condition: Alcohol Dependency
    Disease: Version SOC Term Classification Code Term Level
    16.1 10037175 - Psychiatric disorders 10037175 Psychiatric disorders SOC
    16.1 10037175 - Psychiatric disorders 10001594 Alcohol dependence syndrome LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) ES (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-001524-31 Sponsor Protocol Number: URT-15/PBC Start Date*: 2008-08-26
    Sponsor Name:Dr. Falk Pharma GmbH
    Full Title: Double-blind, double-dummy, randomized, crossover, multicentre phase IV clinical study comparing the effect of Ursofalk® 500 mg tablets od versus Ursofalk® 250 mg capsules od on liver enzyme parame...
    Medical condition: Treatment of primary biliary cirrhosis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10036680 Primary biliary cirrhosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2019-001172-11 Sponsor Protocol Number: MedOPP239 Start Date*: 2020-03-10
    Sponsor Name:Medica Scientia Innovation Research (MedSIR)
    Full Title: A Multicenter, Open-Label, Single-ARm, PHase II Clinical Trial to Evaluate the Efficacy and Safety of INCMGA00012 in Advanced Penile SquamoUS Cell Carcinoma. ORPHEUS Phase II Study of the Efficacy ...
    Medical condition: Unresectable locally advanced or metastatic penile squamous cell carcinoma (PSqCC).
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10034299 Penile cancer PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: ES (Ongoing) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-018982-43 Sponsor Protocol Number: AB08025 Start Date*: 2010-06-18
    Sponsor Name:AB SCIENCE
    Full Title: A prospective, multicenter, open-label, uncontrolled, two-parallel group, phase 1/2 study to evaluate safety and efficacy of masitinib at 9 mg/kg/day in monotherapy and in combination with dacarbaz...
    Medical condition: Mélanome métastasé ou non-opérable stade 3 ou stade 4, ne portant pas de mutation dans le domaine juxta-membranaire de c-kit
    Disease: Version SOC Term Classification Code Term Level
    12.1 10025670 Malignant melanoma stage III LLT
    12.1 10025671 Malignant melanoma stage IV LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-018875-30 Sponsor Protocol Number: BRD10/1-P Start Date*: 2010-04-06
    Sponsor Name:CHU de Nantes
    Full Title: Comparaison de l’effet antisécrétoire d’une dose unique de rabeprazole 20 mg et d’omeprazole 20 mg chez des sujets obèses
    Medical condition: reflus gastro-oesophagien
    Disease: Version SOC Term Classification Code Term Level
    12.1 10017884 Gastrooesophageal reflux LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-005522-29 Sponsor Protocol Number: M14-002 Start Date*: 2013-04-17
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: A Randomized, Double-Blind, Controlled Study to Evaluate the Efficacy and Safety of the Combination of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With and Without Ribavirin (RBV) in ...
    Medical condition: Chronic Hepatitis C Infection
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10008912 Chronic hepatitis C PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2014-002925-36 Sponsor Protocol Number: M14-867 Start Date*: 2015-04-10
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: An Open-Label, Multicenter Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Co-Administration of ABT-493 and ABT-530 With and Without Ribavirin in Subjects with Chronic Hepatitis C V...
    Medical condition: Chronic Hepatitis C Virus (HCV) Infection
    Disease: Version SOC Term Classification Code Term Level
    17.1 10021881 - Infections and infestations 10008912 Chronic hepatitis C PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2007-004603-35 Sponsor Protocol Number: REACH Start Date*: 2009-04-28
    Sponsor Name:University of Heidelberg
    Full Title: Radiotherapy (IMRT), Erbitux And Chemotherapy For Unresectable Carcinomas Of Head and Neck. REACH-Study
    Medical condition: Histologically confirmed locally advanced (stage III or IV), non-metastatic squamous cell carcinoma of oro-, hypopharynx or larynx (T2-4, NX, M0).
    Disease: Version SOC Term Classification Code Term Level
    9.1 10041849 Squamous cell carcinoma of the hypopharynx LLT
    9.1 10023856 Laryngeal squamous cell carcinoma LLT
    9.1 10031112 Oropharyngeal squamous cell carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-006114-14 Sponsor Protocol Number: 62326B1658 Start Date*: 2012-04-17
    Sponsor Name:Research and Development department
    Full Title: “Effects of testosterone on glycaemic control and other Cardiovascular Risk factors in Hypogonadal Men with uncontrolled Type 2 Diabetes: A randomized double – blinded placebo controlled add on tr...
    Medical condition: Hypogonadism Type 2 Diabetes Cardiovascular risk
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2016-002056-25 Sponsor Protocol Number: MK-8521-004 Start Date*: 2016-09-06
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Phase IIa, Multicenter, Placebo- and Active-controlled, Randomized, Double-Blind, Clinical Trial to Evaluate the Safety and Efficacy of MK-8521 Compared to Placebo in Subjects with Type 2 Diabete...
    Medical condition: Type 2 Diabetes Mellitus
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-003192-22 Sponsor Protocol Number: M16-126 Start Date*: 2017-03-08
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: A Multicenter, Open-Label Study to Evaluate the Efficacy and Safety of Glecaprevir (GLE)/Pibrentasvir (PIB) in Adults with Chronic Hepatitis C Virus (HCV) Genotype 5 or 6 Infection.
    Medical condition: Chronic hepatitis C virus genotype 5 or 6 infection, cirrhosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000074171 10019752 Hepatitis C virus (HCV) LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2006-001182-41 Sponsor Protocol Number: C0168X97 Start Date*: 2007-03-27
    Sponsor Name:Ass.Prof. Petros Sfikakis
    Full Title: Infliximab for Diabetic Macular Edema Refractory to Laser Photocoagulation: a Randomized, Double-Masked, Placebo-Controlled, Cross-over, 32 Weeks Study
    Medical condition: Diabetic Macular Oedema
    Disease: Version SOC Term Classification Code Term Level
    8.1 10057915 Diabetic macular oedema LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-001192-29 Sponsor Protocol Number: cv-08/025 Start Date*: 2008-06-03
    Sponsor Name:Fundación Investigación y Desarrollo en el Area Cardiovascular
    Full Title: “Evaluación mediante proteómica de biomarcadores proteicos asociados con el tratamiento con Eplerenona versus espironolactona en pacientes post-infarto agudo de miocardio, diabéticos con hipertensi...
    Medical condition: Disfunción ventricular leve-moderada post-infarto agudo de miocardio en pacientes diabéticos con hipertensión arterial no controlada. Low-moderate ventricular dysfunction in post-acute coronary sy...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon Jun 15 02:54:53 CEST 2026 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA